全文获取类型
收费全文 | 4668篇 |
免费 | 253篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 82篇 |
妇产科学 | 22篇 |
基础医学 | 156篇 |
口腔科学 | 14篇 |
临床医学 | 151篇 |
内科学 | 1613篇 |
皮肤病学 | 10篇 |
神经病学 | 20篇 |
特种医学 | 138篇 |
外科学 | 2223篇 |
综合类 | 23篇 |
预防医学 | 69篇 |
眼科学 | 8篇 |
药学 | 60篇 |
中国医学 | 3篇 |
肿瘤学 | 405篇 |
出版年
2024年 | 1篇 |
2023年 | 305篇 |
2022年 | 564篇 |
2021年 | 367篇 |
2020年 | 355篇 |
2019年 | 265篇 |
2018年 | 209篇 |
2017年 | 204篇 |
2016年 | 162篇 |
2015年 | 169篇 |
2014年 | 340篇 |
2013年 | 307篇 |
2012年 | 225篇 |
2011年 | 172篇 |
2010年 | 171篇 |
2009年 | 167篇 |
2008年 | 124篇 |
2007年 | 124篇 |
2006年 | 143篇 |
2005年 | 109篇 |
2004年 | 80篇 |
2003年 | 86篇 |
2002年 | 57篇 |
2001年 | 64篇 |
2000年 | 51篇 |
1999年 | 32篇 |
1998年 | 28篇 |
1997年 | 20篇 |
1996年 | 19篇 |
1995年 | 32篇 |
1994年 | 18篇 |
1993年 | 8篇 |
1992年 | 9篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1976年 | 1篇 |
排序方式: 共有5001条查询结果,搜索用时 46 毫秒
41.
Vikram Sharma Kevin Chen Shehab A.R. Alansari Beni Verma Edward G. Soltesz Douglas R. Johnston Michael Zhen-Yu Tong Eric E. Roselli Per Wierup Gösta B. Pettersson A. Marc Gillinov Stephen G. Ellis Conrad Simpfendorfer Eugene H. Blackstone Samir Kapadia Lars G. Svensson Faisal G. Bakaeen 《The Annals of thoracic surgery》2021,111(5):1494-1501
42.
Yuki Bekki Josep Marti Takeo Toshima Sara Lewis Amita Kamath Pamela Argiriadi William Simpson Lucas Facciuto Rahul S. Patel Ganesh Gunasekaran Edward Kim Thomas D. Schiano Marcelo E. Facciuto 《Surgery》2021,169(5):1044-1051
BackgroundPortal vein embolization before liver resection is considered the therapy of choice for patients with inadequate future liver remnants. The concept of radioembolization with Yttrium-90 to achieve the same goal has limited data.MethodsWe retrospectively compared patients who underwent portal vein embolization and Yttrium-90 lobectomy before resection of hepatocellular carcinoma in patients with chronic liver disease.ResultsSeventy-three patients underwent portal vein embolization and 22 patients underwent Yttrium-90. Forty-seven percent of patients before portal vein embolization required additional procedures for tumor control, and 27% of patients after Yttrium-90 required additional procedure to mainly induce further hypertrophy. Both therapies achieved the goal of future liver remnants >40%, but the degree of hypertrophy was significantly higher in Yttrium-90 patients (63% for Yttrium-90, 36% for portal vein embolization, P < .01). Tumor response was significantly better with Yttrium-90, achieving complete response in 50% of patients. Resectability rate was higher after portal vein embolization (85% for portal vein embolization, 64% for Yttrium-90, P = .03). Tumor progression was the most common reason precluding surgery. Complete tumor control was the reason not to pursue surgery in 18% of patients after Yttrium-90.ConclusionBoth preoperative portal vein embolization and Yttrium-90, increases liver resectability rates by inducing hypertrophy of future liver remnants in patients with hepatocellular carcinoma and chronic liver disease. Yttrium-90 lobectomy achieved better tumor control and provided more time to assess therapy response, optimizing the indication for surgery. 相似文献
43.
44.
《Transplantation proceedings》2021,53(7):2329-2334
BackgroundThis study measures the first-pass arrival times in the hepatic artery and portal vein of the transplanted liver using contrast-enhanced ultrasound (CEUS) and assess its correlation with graft performance in the early posttransplant period.MethodsThis study evaluated 35 liver transplant recipients who underwent CEUS examination within 1 month of transplant surgery. CEUS under contrast-specific harmonic imaging mode were recorded for 60 seconds immediately after intravenous administration of microbubble ultrasound contrast medium (Sonazoid, GE Healthcare, Oslo, Norway). The recorded video clips were reviewed by 2 readers to determine the first-pass arrival times in the hepatic artery and portal vein, and the difference between the 2 was defined as the arterial-portal arrival interval (APAI). Laboratory data on the same date of CEUS examination were collected as indicators to correlate with APAI.ResultsThe intra- and inter-rater reliability for APAI measurement were excellent, with intraclass correlation coefficients > .95. The mean APAI was 4.5 ± 1.8 seconds (range, 2.0-10.5 seconds). The APAI was positively correlated with the serum total bilirubin level (r = 0.357, P = .035) and negatively correlated with the platelet count (r = −0.354, P = .037). At the 5 second cutoff point, a total serum bilirubin of >8 mg/dL was reported in 5 of 11 patients (45.4%) with APAI of >5 seconds and in only 3 of 24 patients (12.5%) with APAI of <5 seconds (P < .05).ConclusionsThe APAI is a quantitative marker that links the hemodynamics and the clinical status of the liver graft. 相似文献
45.
46.
47.
48.
Giuliante Felice Viganò Luca De Rose Agostino M. Mirza Darius F. Lapointe Réal Kaiser Gernot Barroso Eduardo Ferrero Alessandro Isoniemi Helena Lopez-Ben Santiago Popescu Irinel Ouellet Jean-Francois Hubert Catherine Regimbeau Jean-Marc Lin Jen-Kou Skipenko Oleg G. Ardito Francesco Adam René 《Annals of surgical oncology》2021,28(13):8198-8208
Annals of Surgical Oncology - The liver-first approach in patients with synchronous colorectal liver metastases (CRLM) has gained wide consensus but its role is still to be clarified. We aimed to... 相似文献
49.
Tarek Debs Niccolo Petrucciani Sebastian Frey Carine Korkmaz Katharina Hufschmidt Eric Sejor Houssam Eddine Bitar Imed Ben Amor Antonio Iannelli Jean Gugenheim 《Surgery for obesity and related diseases》2021,17(5):901-908
BackgroundBariatric surgery has become widely performed for treating patients with morbid obesity, and the age limits are being pushed further and further as the procedure proves safe. After massive weight loss, many of those patients seek body-contouring surgery for excess skin and fat.ObjectivesTo analyze the feasibility and the safety of abdominoplasty in patients older than 55 years old after bariatric surgery.SettingUniversity hospital medical center.MethodsWe performed a retrospective review of prospectively collected data from patients aged older than 55 years who had undergone abdominoplasty following massive weight loss due to a bariatric surgery at a single institution from 2004 to 2017. The data analyzed included age, gender, preoperative body mass index, associated interventions, co-morbidities, and postoperative complications.ResultsWe retrieved records for 104 patients; 85.6% percent of them were female, and the mean age was 60.1 ± 3.9 years old. Of the 104 patients, 21 (20.2%) underwent a sleeve gastrectomy and 77 (74%) underwent a Roux-en-Y gastric bypass. The mean interval between the bariatric surgery and the abdominoplasty was 33.6 ± 26.9 months. The mean preoperative weight and body mass index were 76.1 ± 14.5 kg and 28.9 ± 4.5 kg/m2, respectively. A total complication rate of 20% was observed. The only factor significantly associated with postoperative morbidity was the associated procedure (P = .03), when we performed another procedure at the same time as the abdominoplasty. Complications included postoperative bleeding in 5 patients (4.8%), seromas in 5 patients (4.8%), surgical site infections in 12 patients (11.5%), and wound dehiscence or ischemia in 2 patients (1.9%). No mortality occurred.ConclusionAbdominoplasty can be safely performed in carefully selected patients older than 55 years old after weight loss surgery, and does not present increased morbidity or mortality. We recommend that surgeons avoid adding concomitant procedures when possible, to decrease the risk of complications. It is also important to look at the patient’s previous maximum BMI levels, as a higher maximum BMI can predict higher postoperative risks and longer hospital stays. 相似文献
50.
Aránzazu Caballero-Marcos Magdalena Salcedo Roberto Alonso-Fernández Manuel Rodríguez-Perálvarez María Olmedo Javier Graus Morales Valentín Cuervas-Mons Alba Cachero Carmelo Loinaz-Segurola Mercedes Iñarrairaegui Lluís Castells Sonia Pascual Carmen Vinaixa-Aunés Rocío González-Grande Alejandra Otero Santiago Tomé Javier Tejedor-Tejada José María Álamo-Martínez Luisa González-Diéguez Flor Nogueras-Lopez Gerardo Blanco-Fernández Gema Muñoz-Bartolo Francisco Javier Bustamante Emilio Fábrega Mario Romero-Cristóbal Rosa Martin-Mateos Julia Del Rio-Izquierdo Ana Arias-Milla Laura Calatayud Alberto A. Marcacuzco-Quinto Víctor Fernández-Alonso Concepción Gómez-Gavara Jordi Colmenero Patricia Muñoz José A. Pons the Spanish Society of Liver Transplantation 《American journal of transplantation》2021,21(8):2876-2884
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case–control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline. 相似文献